Protein Traffic Disorders: an Effective High-Throughput Fluorescence Microscopy Pipeline for Drug Discovery

被引:48
|
作者
Botelho, Hugo M. [1 ,2 ,3 ]
Uliyakina, Inna [1 ,2 ,3 ]
Awatade, Nikhil T. [1 ]
Proena, Maria C. [1 ]
Tischer, Christian [2 ,3 ]
Sirianant, Lalida [4 ]
Kunzelmann, Karl [4 ]
Pepperkok, Rainer [2 ,3 ]
Amaral, Margarida D. [1 ]
机构
[1] Univ Lisbon, Fac Sci, BioISI Biosyst & Integrat Sci Inst, P-1749016 Lisbon, Portugal
[2] European Mol Biol Lab, Cell Biol & Biophys Unit, D-69117 Heidelberg, Germany
[3] European Mol Biol Lab, Adv Light Microscopy Facil, D-69117 Heidelberg, Germany
[4] Univ Regensburg, Dept Physiol, D-93053 Regensburg, Germany
来源
SCIENTIFIC REPORTS | 2015年 / 5卷
关键词
TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; REVERSE TRANSFECTION; MUTANT CFTR; IN-VITRO; RECEPTOR; GENE; CHANNEL; ASSAYS; EXPRESSION;
D O I
10.1038/srep09038
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Plasma membrane proteins are essential molecules in the cell which mediate interactions with the exterior milieu, thus representing key drug targets for present pharma. Not surprisingly, protein traffic disorders include a large range of diseases sharing the common mechanism of failure in the respective protein to reach the plasma membrane. However, specific therapies for these diseases are remarkably lacking. Herein, we report a robust platform for drug discovery applied to a paradigmatic genetic disorder affecting intracellular trafficking - Cystic Fibrosis. This platform includes (i) two original respiratory epithelial cellular models incorporating an inducible double-tagged traffic reporter; (ii) a plasma membrane protein traffic assay for high-throughput microscopy screening; and (iii) open-source image analysis software to quantify plasma membrane protein traffic. By allowing direct scoring of compounds rescuing the basic traffic defect, this platform enables an effective drug development pipeline, which can be promptly adapted to any traffic disorder-associated protein and leverage therapy development efforts.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] High-throughput multiplexed capillary electrophoresis in drug discovery
    Pang, HM
    Kenseth, J
    Coldiron, S
    DRUG DISCOVERY TODAY, 2004, 9 (24) : 1072 - 1080
  • [32] High-Throughput Transcriptome Profiling in Drug and Biomarker Discovery
    Yang, Xiaonan
    Kui, Ling
    Tang, Min
    Li, Dawei
    Wei, Kunhua
    Chen, Wei
    Miao, Jianhua
    Dong, Yang
    FRONTIERS IN GENETICS, 2020, 11
  • [33] Accelerating drug discovery by high-throughput combinatorial synthesis
    Banville, SC
    Zuckermann, RN
    PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON LABORATORY AUTOMATION AND ROBOTICS 1996, 1997, : 77 - 92
  • [34] High-Throughput crystallographic fragment screening for drug discovery
    Metz, Alexander
    Huschinann, Franziska
    Schiebel, Johannes
    Mueller, Utiye
    Weiss, Manfred
    Heine, Andreas
    Melte, Gerhard
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2018, 74 : E24 - E24
  • [35] High-throughput kinase profiling as a platform for drug discovery
    David M. Goldstein
    Nathanael S. Gray
    Patrick P. Zarrinkar
    Nature Reviews Drug Discovery, 2008, 7 : 391 - 397
  • [36] High-throughput screening approaches to TB drug discovery
    Stanley, Sarah A.
    Grant, Sarah S.
    Barczak, Amy K.
    Hung, Deborah T.
    TUBERCULOSIS, 2013, 93 (01) : 110 - 110
  • [37] Modern analytical approaches to high-throughput drug discovery
    Gomez-Hens, A.
    Aguilar-Caballos, M. P.
    TRAC-TRENDS IN ANALYTICAL CHEMISTRY, 2007, 26 (03) : 171 - 182
  • [38] High-throughput crystallography for lead discovery in drug design
    Blundell, TL
    Jhoti, H
    Abell, C
    NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (01) : 45 - 54
  • [39] High-throughput crystallization and structure determination in drug discovery
    Stewart, L
    Clark, R
    Behnke, C
    DRUG DISCOVERY TODAY, 2002, 7 (03) : 187 - 196
  • [40] High-throughput crystallography for lead discovery in drug design
    Tom L. Blundell
    Harren Jhoti
    Chris Abell
    Nature Reviews Drug Discovery, 2002, 1 : 45 - 54